Final Development Stage For Prolia Reflects Amgen's Eye On Advertising
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech's roll-out of clinical data on the RANK ligand inhibitor no longer is studies that supported the initial application but studies focused on particular claims or comparative advantages that will improve Prolia's commercial outlook.